Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1981 May;32(2):443–448. doi: 10.1128/iai.32.2.443-448.1981

Influence of Mucoid Coating on Clearance of Pseudomonas aeruginosa from Lungs

Linda L Blackwood 1, James E Pennington 1
PMCID: PMC351463  PMID: 6788696

Abstract

Pulmonary infection with mucoid strains of Pseudomonas aeruginosa in present in the majority of cystic fibrosis patients with chronic lung disease. It has been postulated that this mucoid coating may act to decrease lung clearance of Pseudomonas by limiting access of phagocytes, antibodies, and antibiotics to the bacteria. To determine whether mucoid coating of Pseudomonas might decrease intrapulmonary killing, groups of guinea pigs were infected with intrabronchial instillations of equivalent numbers of mucoid and nonmucoid Pseudomonas. For this study, mucoid strains of Pseudomonas were obtained from cystic fibrosis sputa and passaged on blood agar plates to obtain their nonmucoid revertants. Animals were then sacrificed at timed intervals after infection, and quantitative cultures were performed on lung homogenates. In all cases, mucoid challenge strains retained their mucoid morphology after passage in guinea pig lungs. No difference in killing of mucoid and nonmucoid Pseudomonas could be detected at 6, 24, or 48 h after lung infection. Further challenge studies used guinea pigs that were either prevaccinated with lipopolysaccharide P. aeruginosa vaccine or else treated with tobramycin sulfate after infection. Nonvaccinated or untreated controls had reduced intrapulmonary killing of Pseudomonas compared with vaccinees or treated groups (P < 0.02 and P < 0.01, respectively). However, there were no differences in pulmonary killing of mucoid and nonmucoid Pseudomonas in the presence of either specific antibodies or antibiotic. We conclude from these studies that mucoid coating of Pseudomonas does not selectively impede mechanisms of intrapulmonary killing in guinea pig lungs.

Full text

PDF
443

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baltimore R. S., Mitchell M. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. J Infect Dis. 1980 Feb;141(2):238–247. doi: 10.1093/infdis/141.2.238. [DOI] [PubMed] [Google Scholar]
  2. Cash H. A., Woods D. E., McCullough B., Johanson W. G., Jr, Bass J. A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis. 1979 Mar;119(3):453–459. doi: 10.1164/arrd.1979.119.3.453. [DOI] [PubMed] [Google Scholar]
  3. Diaz E., Mosovich L. L., Neter E. Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis. J Infect Dis. 1970 Mar;121(3):269–274. doi: 10.1093/infdis/121.3.269. [DOI] [PubMed] [Google Scholar]
  4. Doggett R. G., Harrison G. M., Carter R. E. Mucoid Pseudomonas aeruginosa in patients with chronic illnesses. Lancet. 1971 Jan 30;1(7692):236–237. doi: 10.1016/s0140-6736(71)90973-1. [DOI] [PubMed] [Google Scholar]
  5. Fisher M. W., Devlin H. B., Gnabasik F. J. New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol. 1969 May;98(2):835–836. doi: 10.1128/jb.98.2.835-836.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldstein E., Lippert W., Warshauer D. Pulmonary alveolar macrophage. Defender against bacterial infection of the lung. J Clin Invest. 1974 Sep;54(3):519–528. doi: 10.1172/JCI107788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Govan J. R., Fyfe J. A. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother. 1978 May;4(3):233–240. doi: 10.1093/jac/4.3.233. [DOI] [PubMed] [Google Scholar]
  8. Hanessian S., Regan W., Watson D., Haskell T. H. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol. 1971 Feb 17;229(7):209–210. doi: 10.1038/newbio229209a0. [DOI] [PubMed] [Google Scholar]
  9. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):551–558. [PubMed] [Google Scholar]
  10. Klinger J. D., Straus D. C., Hilton C. B., Bass J. A. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis. 1978 Jul;138(1):49–48. doi: 10.1093/infdis/138.1.49. [DOI] [PubMed] [Google Scholar]
  11. Lam J., Chan R., Lam K., Costerton J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun. 1980 May;28(2):546–556. doi: 10.1128/iai.28.2.546-556.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Linker A., Jones R. S. A new polysaccharide resembling alginic acid isolated from pseudomonads. J Biol Chem. 1966 Aug 25;241(16):3845–3851. [PubMed] [Google Scholar]
  13. Mackie E. B., Brown K. N., Lam J., Costerton J. W. Morphological stabilization of capsules of group B streptococci, types Ia, Ib, II, and III, with specific antibody. J Bacteriol. 1979 May;138(2):609–617. doi: 10.1128/jb.138.2.609-617.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marrie T. J., Harding G. K., Ronald A. R., Dikkema J., Lam J., Hoban S., Costerton J. W. Influence of mucoidy on antibody coating of Pseudomonas aeruginosa. J Infect Dis. 1979 Mar;139(3):357–361. doi: 10.1093/infdis/139.3.357. [DOI] [PubMed] [Google Scholar]
  15. Matthews W. J., Jr, Williams M., Oliphint B., Geha R., Colten H. R. Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med. 1980 Jan 31;302(5):245–249. doi: 10.1056/NEJM198001313020501. [DOI] [PubMed] [Google Scholar]
  16. Pennington J. E. Differential effects of cyclophosphamide and cortisone acetate on bronchoalveolar phagocytic cell populations. Am Rev Respir Dis. 1978 Aug;118(2):319–324. doi: 10.1164/arrd.1978.118.2.319. [DOI] [PubMed] [Google Scholar]
  17. Pennington J. E., Ehrie M. G. Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression. J Infect Dis. 1978 Jun;137(6):764–774. doi: 10.1093/infdis/137.6.764. [DOI] [PubMed] [Google Scholar]
  18. Pennington J. E., Kuchmy D. Mechanism for pulmonary protection by lipopolysaccharide pseudomonas vaccine. J Infect Dis. 1980 Aug;142(2):191–198. doi: 10.1093/infdis/142.2.191. [DOI] [PubMed] [Google Scholar]
  19. Pennington J. E. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis. 1979 Jul;140(1):73–80. doi: 10.1093/infdis/140.1.73. [DOI] [PubMed] [Google Scholar]
  20. Pennington J. E., Miler J. J. Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun. 1979 Sep;25(3):1029–1034. doi: 10.1128/iai.25.3.1029-1034.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pennington J. E., Stone R. M. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec;140(6):881–889. doi: 10.1093/infdis/140.6.881. [DOI] [PubMed] [Google Scholar]
  22. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies. Ann Intern Med. 1975 Jun;82(6):819–831. doi: 10.7326/0003-4819-82-6-819. [DOI] [PubMed] [Google Scholar]
  23. Schwarzmann S., Boring J. R. Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa. Infect Immun. 1971 Jun;3(6):762–767. doi: 10.1128/iai.3.6.762-767.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shwachman H., Kowalski M., Khaw K. T. Cystic fibrosis: a new outlook. 70 patients above 25 years of age. Medicine (Baltimore) 1977 Mar;56(2):129–149. [PubMed] [Google Scholar]
  25. Thomassen M. J., Demko C. A., Boxerbaum B., Stern R. C., Kuchenbrod P. J. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. doi: 10.1093/infdis/140.6.873. [DOI] [PubMed] [Google Scholar]
  26. Wood R. E., Boat T. F., Doershuk C. F. Cystic fibrosis. Am Rev Respir Dis. 1976 Jun;113(6):833–878. doi: 10.1164/arrd.1976.113.6.833. [DOI] [PubMed] [Google Scholar]
  27. di Sant'agnese P. A., Davis P. B. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med. 1979 Jan;66(1):121–132. doi: 10.1016/0002-9343(79)90491-1. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES